Changing of the Guard: Investing in Life Sciences September 22, 2011

Changing of the Guard: Investing in Life Sciences

The significant costs, extended timelines, and regulatory hurdles facing emerging life science companies in today's economy make it increasingly difficult for VCs to make a sizable return on their investment. Can the same be said for corporate investors, or do they have different objectives? What is driving their investment strategy? Is it strategic alignment, an attempt at harnessing innovation, or simply good business? Join us at our next industry panel for an interactive discussion on why and how corporate players are getting in the game and hitting it big! Could this be the changing of the guard in life sciences? Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

CONFIRMED & INVITED PANELISTS

Tiba Aynechi, Principal in Novo Ventures, Novo A/S

Martin Eglitis, Senior Partnering Director, Teva Pharmaceuticals

Juan Harrison, Vice President, Takeda Research Investment

Brian Piper, Senior Director, Strategic Investment Group, Shire Pharmaceuticals

Official Website: http://sjbiocenter.com/event/ev_2011Q3-COG-InvestinginLifeSciences